TY - JOUR
T1 - AXIN2-related oligodontia-colorectal cancer syndrome with cleft palate as a possible new feature
AU - Roht, Laura
AU - Hyldebrandt, Hanne K.
AU - Stormorken, Astrid T.
AU - Nordgarden, Hilde
AU - Sijmons, Rolf H.
AU - Bos, Dennis K.
AU - Riegert-Johnson, Douglas
AU - Mantia-Macklin, Sarah
AU - Ilves, Pilvi
AU - Muru, Kai
AU - Wojcik, Monica H.
AU - Kahre, Tiina
AU - Õunap, Katrin
N1 - Funding Information:
This work was supported by Estonian Research Council grant PRG471. Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and were funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1 HG008900 and in part by National Human Genome Research Institute grant R01 HG009141.
Funding Information:
This work is generated within the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)—Project ID No 739547. ERN GENTURIS is partly co‐funded by the European Union within the framework of the Third Health Programme “ERN‐2016—Framework Partnership Agreement 2017–2021.”
Publisher Copyright:
© 2023 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
PY - 2023/6
Y1 - 2023/6
N2 - Background: Pathogenic variants in AXIN2 have been associated with tooth agenesis, colon polyps, and colon cancer. Given the rare nature of this phenotype, we set out to collect additional genotypic and phenotypic information. Methods: Data were collected via a structured questionnaire. Sequencing was performed in these patients mostly due to diagnostic purpose. A little more than half of the AXIN2 variant carriers were identified by NGS; other six were family members. Results: Here, we report 13 individuals with a heterozygous AXIN2 pathogenic/likely pathogenic variant who have a variable expression of oligodontia-colorectal cancer syndrome (OMIM 608615) or oligodontia-cancer predisposition syndrome (ORPHA 300576). Three individuals from one family also had cleft palate, which might represent a new clinical feature of AXIN2 phenotype, also given the fact that AXIN2 polymorphisms have been found in association with oral clefting in population studies. AXIN2 has already been added to multigene cancer panel tests; further research should be conducted to determine whether it should be added to cleft lip/palate multigene panels. Conclusion: More clarity about oligodontia-colorectal cancer syndrome, about the variable expression, and associated cancer risks is needed to improve clinical management and to establish guidelines for surveillance. We collected information about the surveillance that was advised, which might support clinical management of these patients.
AB - Background: Pathogenic variants in AXIN2 have been associated with tooth agenesis, colon polyps, and colon cancer. Given the rare nature of this phenotype, we set out to collect additional genotypic and phenotypic information. Methods: Data were collected via a structured questionnaire. Sequencing was performed in these patients mostly due to diagnostic purpose. A little more than half of the AXIN2 variant carriers were identified by NGS; other six were family members. Results: Here, we report 13 individuals with a heterozygous AXIN2 pathogenic/likely pathogenic variant who have a variable expression of oligodontia-colorectal cancer syndrome (OMIM 608615) or oligodontia-cancer predisposition syndrome (ORPHA 300576). Three individuals from one family also had cleft palate, which might represent a new clinical feature of AXIN2 phenotype, also given the fact that AXIN2 polymorphisms have been found in association with oral clefting in population studies. AXIN2 has already been added to multigene cancer panel tests; further research should be conducted to determine whether it should be added to cleft lip/palate multigene panels. Conclusion: More clarity about oligodontia-colorectal cancer syndrome, about the variable expression, and associated cancer risks is needed to improve clinical management and to establish guidelines for surveillance. We collected information about the surveillance that was advised, which might support clinical management of these patients.
KW - AXIN2
KW - cancer predisposition syndrome
KW - cleft palate
KW - oligodontia
U2 - 10.1002/mgg3.2157
DO - 10.1002/mgg3.2157
M3 - Article
AN - SCOPUS:85149421783
SN - 2324-9269
VL - 11
JO - Molecular Genetics and Genomic Medicine
JF - Molecular Genetics and Genomic Medicine
IS - 6
M1 - e2157
ER -